無料プレビュー

Alnylam Pharmaceuticals, Inc. (ALNY) · NASDAQ Global Select

プロフィール

Alnylam Pharmaceuticals is a global biopharmaceutical company developing RNAi (ribonucleic acid interference) therapeutics that silence disease-causing genes by targeting messenger RNA. The company markets six approved RNAi medicines: AMVUTTRA & ONPATTRO for transthyretin amyloidosis, GIVLAARI for acute hepatic porphyria, OXLUMO for primary hyperoxaluria type 1, Leqvio (via Novartis) for hypercholesterolemia, and Qfitlia (via Sanofi) for hemophilia. Alnylam operates a clinical pipeline of 20+ programs targeting rare and prevalent diseases through proprietary delivery platforms for hepatic, cen

主要指標

株価: $224.53 (+0.05%)
時価総額: 300億ドル
PER（今期予想）: 33.7
PBR: 22.1
配当利回り: —
52週レンジ: $197.81 – $495.55
業種: Healthcare / Biotechnology
上場: NASDAQ Global Select
構成銘柄: Nasdaq 100 0.12%

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、ROIV Roivant Sciences Ltd.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-10-29 · 更新: 2026-10-09